Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company's innovative portfolio directed against RAS cancers.

The R&D update covers the latest developments across certain of the company’s programs including:

• Update on the broad RMC-4630 clinical development program, including new data sets from the ongoing Phase 1 monotherapy clinical trial (RMC-4630-01)
  
  -  New pharmacokinetic profiles and improved tolerability with intermittent dosing schedules
  
  -  Expanded experience of anti-tumor activity in non-small cell lung cancer patients carrying KRAS mutations
  
  -  New anti-tumor activity in patients carrying NF1^LOF mutations
  
  -  Recap of recent RMC-4630-related announcements with update on overall program status

• Highlights of in vivo preclinical data demonstrating induction of anti-tumor immunity via adaptive and innate immune systems by SHP2 inhibitor monotherapy and combination treatment with a checkpoint inhibitor, as reported in a recent publication by company scientists in Cancer Research
   
• New in vivo data on dual targeted therapy with mTORC1-selective inhibitor and KRAS^G12C(OFF) inhibitor in preclinical models of resistance to monotherapy
   
• New in vivo data on pharmacokinetic profile and anti-tumor responses to oral administration of novel KRAS^G12C(ON) inhibitor

To access full details of the R&D update, please review the company’s investor presentation within the investor section of the company’s website at: https://ir.revmed.com/events-and-presentations. The updated presentation has also been furnished with the U.S. Securities and Exchange Commission (SEC).

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive high-value frontier cancer targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.